Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

(1) Background: Colorectal cancer (CRC) is the third most common cancer and the second
leading cause of cancer-related mortality worldwide. Up to 50% of patients with CRC …

Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

Background The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus
bevacizumab showed improved outcomes for patients with metastatic colorectal cancer …

This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic
therapy in metastatic disease. Considerations for treatment selection among 32 different …

Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and
irinotecan) plus bevacizumab significantly improved progression-free survival of patients …

Background The definition of a best maintenance strategy following combination
chemotherapy plus bevacizumab in metastatic colorectal cancer is unclear. We investigated …

The response to first-line therapy is a primary determinant of outcome in patients with
metastatic colorectal cancer (mCRC), for three main reasons: effective upfront therapy …

Gold nanoparticles (AuNPs) have undergone significant research for their use in the
treatment of cancer. Numerous researchers have established their potent antitumor …